非传统合成改善病情抗风湿药对类风湿关节炎相关间质性肺疾病患者的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入17项研究、1315例类风湿关节炎相关间质性肺疾病(RA-ILD)患者,评估非传统合成改善病情抗风湿药(ncs-DMARD)的疗效。汇总数据显示ncs-DMARD治疗(单用或联合传统治疗)后用力肺活量(FVC)、第一秒用力呼气容积(FEV1)和一氧化碳弥散量(DLCO)较基线无显著变化;利妥昔单抗亚组FVC明显增加。高分辨率CT无进展率为0.792,ILD进展所致病死率为0.049。作者认为ncs-DMARD单用或联合传统治疗可能是稳定或改善RA-ILD的较优且有前景的治疗。
要点
- 汇总ncs-DMARD治疗(单用或联合传统治疗)后FVC、FEV1、DLCO较基线无显著变化。
- 利妥昔单抗亚组FVC明显增加(MD=-4.62,95%CI -8.90至-0.33,p=0.03)。
- 高分辨率CT无进展率为0.792(95%CI 0.746至0.834),ILD进展所致病死率为0.049(95%CI 0.035至0.065)。
核心结论
- ncs-DMARD单用或联合传统治疗可能是稳定或改善RA-ILD患者间质性肺疾病的较优且有前景的治疗。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Cochrane图书馆和Web of Science自建库至2022年6月1日的相关文献。
- 共纳入17项研究、1315例RA-ILD患者,ncs-DMARD包括阿巴西普、利妥昔单抗、托珠单抗、肿瘤坏死因子抑制剂和Janus激酶抑制剂。
- 分析结果以均数差(MD)、效应量和95%CI表示。
主要发现
- 与基线相比,ncs-DMARD治疗(单用或联合传统治疗)后汇总数据的FVC、FEV1和DLCO值无显著变化(FVC p=0.36;FEV1 p=0.96;DLCO p=0.46)。
- 利妥昔单抗亚组FVC明显增加(MD=-4.62,95%CI -8.90至-0.33,p=0.03)。
- RA-ILD患者高分辨率CT无进展率为0.792(95%CI 0.746至0.834,p=0.015),ILD进展所致病死率为0.049(95%CI 0.035至0.065,p=0.000)。
关键数值与推荐
- 利妥昔单抗亚组FVC的MD为-4.62(95%CI -8.90至-0.33,p=0.03)。
- 高分辨率CT无进展率为0.792(95%CI 0.746至0.834,p=0.015)。
- ILD进展所致病死率为0.049(95%CI 0.035至0.065,p=0.000)。
- 汇总数据FVC变化p=0.36、FEV1变化p=0.96、DLCO变化p=0.46。
临床怎么用
- 作者认为ncs-DMARD单用或联合传统治疗可能是稳定或改善RA-ILD患者间质性肺疾病的较优且有前景的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We conducted a systematic review and meta-analysis to determine the efficacy of non-conventional synthetic disease-modifying antirheumatic drug (ncs-DMARD) strategies on patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). METHODS: PubMed, EMBASE, the Cochrane Library and Web of Science were searched for relevant articles from inception to 1 June 2022. The results obtained from the analysis were expressed as mean difference (MD), effect size and 95% CI. RESULTS: A total of 17 studies, including 1315 patients with RA-ILD, were eligible. The ncs-DMARDs included abatacept, rituximab, tocilizumab, tumour necrosis factor and Janus kinase inhibitors. Compared with the baseline, there were no significant changes in forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) values in the pooled data after ncs-DMARD treatment (alone or combined with conventional therapy) (p=0.36 for FVC; p=0.96 for FEV1 and p=0.46 for DLCO). Of note, FVC was obviously increased in rituximab subgroup (MD=-4.62, 95% CI -8.90 to -0.33, p=0.03). Also, high-resolution CT non-progression rate and fatality rate due to ILD progression in patients with RA-ILD were 0.792 (95% CI 0.746 to 0.834, p=0.015) and 0.049 (95% CI 0.035 to 0.065, p=0.000), respectively. CONCLUSION: ncs-DMARDs alone or combined with conventional therapy might be an optimal and promising treatment for stabilising or improving ILD in patients with RA-ILD. PROSPERO REGISTRATION NUMBER: CRD42022356816.
引用
- Yuan H, Cui S, Yang L, et al. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open. 2023. PMID: 37899093. doi:10.1136/rmdopen-2023-003487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。